Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:FSTXNASDAQ:OBSVNASDAQ:SPPINASDAQ:STSANASDAQ:VIRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFSTXF-star Therapeutics$7.12$6.19$2.07▼$7.12$156.50M0.85709,213 shsN/AOBSVObsEva$0.01$0.01$0.08▼$2.14$390K0.688.94 million shs10,550 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/ASTSASatsuma Pharmaceuticals$1.10-0.9%$1.08$0.59▼$8.08$36.47M0.1701,788 shs1.83 million shsVIRXViracta Therapeutics$0.81-3.6%$0.95$0.43▼$2.38$31.82M0.95133,594 shs33,087 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFSTXF-star Therapeutics0.00%0.00%0.00%0.00%0.00%OBSVObsEva+2,400.00%0.00%-60.00%-91.67%-94.05%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%-6.36%STSASatsuma Pharmaceuticals0.00%0.00%0.00%0.00%+5.77%VIRXViracta Therapeutics-3.55%-2.51%-25.67%+30.89%-28.30%Biden to Launch “FedNOW” [Move Your Money Now] (Ad)Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFSTXF-star TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVIRXViracta Therapeutics0.9651 of 5 stars3.52.00.00.00.00.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFSTXF-star TherapeuticsN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/ASPPISpectrum Pharmaceuticals2.00HoldN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/AVIRXViracta Therapeutics3.00Buy$7.00763.98% UpsideCurrent Analyst RatingsLatest SPPI, VIRX, OBSV, STSA, and FSTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2024VIRXViracta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$13.004/16/2024VIRXViracta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFSTXF-star Therapeutics$21.17M7.39N/AN/A$4.70 per share1.51OBSVObsEva$20.11M0.02N/AN/A$0.41 per share0.01SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87STSASatsuma PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/AVIRXViracta TherapeuticsN/AN/AN/AN/A$0.33 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFSTXF-star Therapeutics-$31.28M-$1.82N/AN/AN/AN/A-57.08%-42.40%N/AOBSVObsEva-$58.38M-$0.92N/A∞N/AN/A-416.36%-92.01%N/ASPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/ASTSASatsuma Pharmaceuticals-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/AVIRXViracta Therapeutics-$51.06M-$1.32N/AN/AN/AN/A-172.32%-71.40%5/13/2024 (Estimated)Latest SPPI, VIRX, OBSV, STSA, and FSTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023VIRXViracta Therapeutics-$0.30-$0.35-$0.05-$0.35N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFSTXF-star TherapeuticsN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/AN/AVIRXViracta TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFSTXF-star Therapeutics0.153.383.38OBSVObsEvaN/A0.610.61SPPISpectrum PharmaceuticalsN/A2.712.38STSASatsuma PharmaceuticalsN/A7.447.44VIRXViracta TherapeuticsN/A1.431.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFSTXF-star Therapeutics31.50%OBSVObsEva17.52%SPPISpectrum Pharmaceuticals21.67%STSASatsuma Pharmaceuticals93.26%VIRXViracta Therapeutics31.37%Insider OwnershipCompanyInsider OwnershipFSTXF-star Therapeutics3.20%OBSVObsEva14.40%SPPISpectrum Pharmaceuticals2.70%STSASatsuma Pharmaceuticals31.20%VIRXViracta Therapeutics7.42%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableFSTXF-star Therapeutics8421.98 million21.28 millionNot OptionableOBSVObsEva4877.97 million66.74 millionNot OptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableSTSASatsuma Pharmaceuticals2133.15 million22.81 millionNot OptionableVIRXViracta Therapeutics4039.27 million36.36 millionOptionableSPPI, VIRX, OBSV, STSA, and FSTX HeadlinesSourceHeadlineDay One wins FDA nod for brain cancer therapy, Ojemdamsn.com - April 23 at 3:26 PMPromising Clinical Trial Results Reinforce Buy Rating for Viracta Therapeuticsmarkets.businessinsider.com - April 18 at 7:46 AMAnalysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)markets.businessinsider.com - April 17 at 12:57 PMAnalysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)markets.businessinsider.com - April 16 at 3:51 PMViracta Eyes FDA Accelerated Approval Path for Nana-val in EBV-Positive PTCLprecisionmedicineonline.com - April 16 at 10:50 AMWhy Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?msn.com - April 15 at 1:27 PMViracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphomaglobenewswire.com - April 15 at 8:00 AMViracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwanglobenewswire.com - April 1 at 8:30 AMViracta Therapeutics CFO and COO Dan Chevallard resignsinvesting.com - March 22 at 9:44 PMBuy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid Financialsmarkets.businessinsider.com - March 12 at 2:39 PMVIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023msn.com - March 8 at 9:38 AMViracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 7 at 4:05 PMViracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trialglobenewswire.com - February 29 at 8:00 AMVIRX Mar 2024 2.500 callfinance.yahoo.com - February 17 at 9:42 AMViracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 6 at 8:23 PMViracta Therapeutics Provides Clinical Update and Outlook for 2024finance.yahoo.com - January 4 at 10:14 AMTaking a Closer Look At Viracta Therapeutics Inc (VIRX) Following Its Recent Tradeknoxdaily.com - January 1 at 8:28 AMViracta Therapeutics Stock (NASDAQ:VIRX) Dividends: History, Yield and Datesbenzinga.com - December 22 at 7:49 PMViracta gets orphan drug status for Nana-val for EBV tumorsmsn.com - December 12 at 3:20 PMViracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinomafinance.yahoo.com - December 12 at 10:19 AMViracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levelsfinance.yahoo.com - December 4 at 9:39 AMViracta Therapeutics Inc VIRXmorningstar.com - November 18 at 2:25 PMA company insider recently sold 3,512 shares of Viracta Therapeutics Inc [VIRX]. Should You Sale?knoxdaily.com - November 9 at 11:39 PMViracta Therapeutics: Q3 Earnings Insightsbenzinga.com - November 9 at 1:39 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsF-star TherapeuticsNASDAQ:FSTXF-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.ObsEvaNASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Spectrum PharmaceuticalsNASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Satsuma PharmaceuticalsNASDAQ:STSASatsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Viracta TherapeuticsNASDAQ:VIRXViracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.